 SEATTLE, Nov. 08, 2022 GLOBE NEWSWIRE -- Icosavax, Inc. Nasdaq: ICVX, a biopharmaceutical company leveraging its innovative virus-like particle VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in and host one-on-one meetings at the following investor conferences: 